Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

432
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

261
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
261
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

303
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
303
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

462
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
462

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of Inpatient Clinical Pharmacists.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Medication Dosing by Advanced Technologies: Promise on the Horizon but Not Without Risk.

Pharmacotherapy·2026
Same author

Creating Solutions to the Challenges in Managing Heparin Infusions: Exploring Use of Technology Including Artificial Intelligence and the Role of Anticoagulation Stewardship.

The Annals of pharmacotherapy·2025
Same author

Reversing Anticoagulants: Influence of Anticoagulation Stewardship and Key Considerations for Optimizing Outcomes.

The Annals of pharmacotherapy·2025
Same author

Considerations in educating patients receiving oral anticoagulation: Quality over quantity.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Temporarily Reversing Warfarin With Low-Dose 4-Factor Prothrombin Complex Concentrate in Left Ventricular Assist Device Patients Undergoing an Invasive Procedure.

The Annals of pharmacotherapy·2024

Related Experiment Video

Updated: Mar 9, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.

Elizabeth M Van Cott1, A Joshua Roberts2, William E Dager2

  • 1Department of Pathology GRJ235, Massachusetts General Hospital, Boston, Massachusetts.

Seminars in Thrombosis and Hemostasis
|January 5, 2017
PubMed
Summary

Parenteral direct thrombin inhibitors (DTIs) like argatroban and bivalirudin offer anticoagulation without heparin, crucial for heparin-induced thrombocytopenia (HIT) and cardiovascular interventions. Monitoring involves activated partial thromboplastin time (aPTT) and activated clotting time (ACT).

More Related Videos

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

10.2K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Related Experiment Videos

Last Updated: Mar 9, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

10.2K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Parenteral direct thrombin inhibitors (DTIs), argatroban and bivalirudin, inhibit thrombin activity.
  • Unlike heparin, DTIs can target both soluble and clot-bound thrombin without needing antithrombin.
  • DTIs are vital alternatives for patients with heparin-induced thrombocytopenia (HIT) or allergies, and for anticoagulation during cardiovascular procedures.

Purpose of the Study:

  • To review the clinical applications of parenteral DTIs.
  • To discuss laboratory assays for monitoring DTI anticoagulant effects.
  • To provide guidance on DTI dosing and monitoring based on clinical indications.

Main Methods:

  • Review of literature on argatroban and bivalirudin.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Examination of laboratory monitoring techniques, including aPTT, ACT, and others.
  • Discussion of therapeutic ranges for specific clinical scenarios like HIT and percutaneous coronary intervention.

Main Results:

  • Argatroban and bivalirudin are effective DTIs with short half-lives in patients without organ failure.
  • Argatroban is liver-eliminated; bivalirudin undergoes proteolytic cleavage and renal clearance.
  • Monitoring typically uses aPTT or ACT, with specific targets for HIT and periprocedural anticoagulation.
  • DTIs can affect the international normalized ratio (INR).

Conclusions:

  • Parenteral DTIs are valuable anticoagulants for specific patient populations and procedures.
  • Appropriate laboratory monitoring is essential for safe and effective DTI use.
  • Understanding drug-specific clearance mechanisms aids in managing anticoagulation intensity.